Komori
Daito Pharmaceutical (4577) · RiskMitigated

Side Effects, Foreign-Matter Contamination and Product Recall Risks

First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2020.

5entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2018WorsenedFY20192016: 120162017: 120172018: 120182019: 120192020: 12020
Same theme, other companies

1 other company's latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2020MitigatedAnnual report

    「To address these risks, the Group has established quality-control and quality-assurance systems and is working to reduce risk, while also taking measures such as purchasing product liability insurance.」

    As measures addressing risks related to side effects, foreign-matter contamination, product recalls and defective health-food quality, it specifies quality-control and quality-assurance systems and product liability insurance.
  2. FY2019WorsenedAnnual report

    「The Group also sells health foods. If an incident occurs in which consumers suffer harm to their health due to defective quality or other factors, the Group's business performance and other results may be affected by a decline in sales of the products concerned, damages claims or damage to the Group's brand image.」

    Explicitly notes the risks of health damage caused by defective health-food quality, damages claims and brand damage, in addition to the existing risks involving pharmaceutical side effects and foreign-matter contamination.
  3. FY2018RestatedAnnual report

    「After a pharmaceutical product is launched, unexpected side effects may be identified, or foreign matter may be found in products during the manufacturing process.」

    Continues to note the risks of side effects, foreign-matter contamination, sales suspension, product recalls and damages claims.
  4. FY2017RestatedAnnual report

    「After a pharmaceutical product is launched, unexpected side effects may be identified, or foreign matter may be found in products during the manufacturing process.」

    Continues to note the risks of side effects, foreign-matter contamination, product recalls, sales suspension and damages claims.
  5. FY2016First statedAnnual report

    「Unexpected side effects may be identified before launch, or foreign matter may be found in products during the manufacturing process.」

    Notes the possibility of sales suspension, product recalls, damages claims and damage to the brand image.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Side Effects, Foreign-Matter Contamination and Product Recall Risks | Daito Pharmaceutical Co.,Ltd. (4577) | Komori